![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Wenzhou Medical College |
---|---|
Information provided by: | Wenzhou Medical College |
ClinicalTrials.gov Identifier: | NCT00686114 |
This study is multi-center randomized phase III one to evaluate the difference in local-control and survival rate between patients receiving concurrent chemoradiotherapy combined Tarceva or not.
Condition | Intervention | Phase |
---|---|---|
Esophageal Cancer |
Drug: Paclitaxel Drug: Cisplatin Drug: Tarceva |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Caregiver), Placebo Control, Parallel Assignment, Bio-equivalence Study |
Official Title: | Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-Center Trial. |
Estimated Enrollment: | 300 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | March 2013 |
Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Enlarged field + Paclitaxel + Cisplatin + Tarceva
|
Drug: Paclitaxel
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
Drug: Cisplatin
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
Drug: Tarceva
150mg/per day,oral administration, from day 1 to day 42 (after the beginning of therapy)
|
B: Experimental
Enlarged field + Paclitaxel + Cisplatin
|
Drug: Paclitaxel
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
Drug: Cisplatin
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
|
C: Active Comparator
Conformal field + Paclitaxel + Cisplatin + Tarceva
|
Drug: Paclitaxel
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
Drug: Cisplatin
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
Drug: Tarceva
150mg/per day,oral administration, from day 1 to day 42 (after the beginning of therapy)
|
D: Active Comparator
Conformal field + Paclitaxel + Cisplatin
|
Drug: Paclitaxel
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
Drug: Cisplatin
135mg/m2,IV,a 28days cycle start on day 1 and day 29 from the beginning of radiotherapy.
|
For the esophageal carcinoma in II~III stage,routine dosage of Paclitaxel and platinum medicine chemotherapy concurrently radical radiotherapy is worthy to be studied. On this base, we advanced approach the enlarged field radiotherapy and the intervention of Tarceva. And approach the therapeutic effect for this method in theoretically, which may give a further reasonable guidance for the clinical therapy.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Shixiu Wu, MD | 86-0577-8806-9372 | wushixiu@medmail.com.cn |
China, Zhe Jiang Province | |
1st affliated hospital of Wen Zhou Medical college | |
Wen Zhou City, Zhe Jiang Province, China, 325000 |
Principal Investigator: | Shixiu Wu, MD | 1st affliated hospital of Wen Zhou Medical college |
Responsible Party: | the first affilated hospital of Wenzhou Medical College ( Li Gang ) |
Study ID Numbers: | Shixiu - 1 |
Study First Received: | May 27, 2008 |
Last Updated: | May 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00686114 |
Health Authority: | China: Ministry of Health |
CR PR NC PD Survival |
Erlotinib Digestive System Neoplasms Esophageal disorder Gastrointestinal Diseases Esophageal Neoplasms Carcinoma Digestive System Diseases |
Cisplatin Paclitaxel Head and Neck Neoplasms Gastrointestinal Neoplasms Esophageal Diseases Esophageal neoplasm |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Mitosis Modulators Enzyme Inhibitors Antimitotic Agents Protein Kinase Inhibitors |
Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses Tubulin Modulators Antineoplastic Agents, Phytogenic |